Lapatinib in the treatment of breast cancer

Expert Review of Anticancer Therapy

Volumn 7, Issue 9, 2007, Pages 1183-1192

  Higa, Gerald M ^a   Abraham, Jame ^b  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

EGFR; ErbB family; HER2; Lapatinib; Receptor tyrosine kinase; Trastuzumab

Indexed keywords

ANTHRACYCLINE DERIVATIVE; AROMATASE INHIBITOR; CAPECITABINE; CETUXIMAB; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; FLUOROPYRIMIDINE; GEFITINIB; IMATINIB; IRINOTECAN; LAPATINIB; LETROZOLE; PACLITAXEL; PLACEBO; TAXANE DERIVATIVE; TRASTUZUMAB; TYVERB; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BRAIN METASTASIS; BREAST CANCER; CANCER GROWTH; CANCER RELAPSE; CANCER RESISTANCE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLON CANCER; COMBINATION CHEMOTHERAPY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DYSPEPSIA; FATIGUE; GENE OVEREXPRESSION; HUMAN; INTESTINE OBSTRUCTION; MONOTHERAPY; NAUSEA; NONHUMAN; OVERALL SURVIVAL; PROGNOSIS; REVIEW; TUMOR REGRESSION;

BIOLOGICAL MARKERS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; GENES, ERBB-2; HUMANS; QUINAZOLINES;

EID: 34948845576     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.7.9.1183     Document Type: Review

References (61)

1. Jensen EV, DeSombre ER, Jungblut PW. Estrogen receptors in hormone-responsive tissues and tumors. In: Endogenous Factors Influencing Host-Tumor Balance. Wissler RW, Dao TL, Wood S Jr (Eds). University of Chicago Press, IL, USA 15-30 (1967).
2. Nowell PC. The minute chromosome (Ph1) in chronic granulocytic leukemia. Blut 8, 65-66 (1962).
3. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/ neu oncogene. Science 235(4785), 177-182 (1987).
4. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353(16), 1673-1684 (2005).
5. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353(16), 1659-1672 (2005).
6. Montemurro F, Donadio M, Clavarezza M et al. Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy. Oncologist 11(4), 318-324 (2006).
7. Bartsch R, Wenzel C, Hussian D et al. Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: an observational study. BMC Cancer 6, 63-68 (2006).
8. Garcia-Saenz JA, Martin M, Puente J et al. Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer. Clin. Breast Cancer 6, 325-329 (2005).
9. Gelmon KA, Mackey J, Verma S et al. Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories. Clin. Breast Cancer 5(1), 52-58 (2004).
10. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 355(26), 2733-2743 (2006).
11. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 103(2), 211-225 (2000).
12. Garrett TP, McKern NM, Lou M et al. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation poised to interact with other ErbB receptors. Mol. Cell 11(2), 495-505 (2003).
13. Jones FE, Stern DF. Expression of dominant-negative ErbB2 in the mammary gland of transgenic mice reveals a role in lobuloalveolar development and lactation. Oncogene 18(23), 3481-3490 (1999).
14. Jones FE, Welte T, Fu XY, Stern DF. ErbB4 signaling in the mammary gland is required for lobuloalveolar development and Stat5 activation during lactation. J. Cell Biol. 147(1), 77-87 (1999).
15. Harris AL, Nicholson S, Sainsbury R, Wright C, Farndon J. Epidermal growth factor receptor and other oncogenes as prognostic markers. Natl Cancer Inst. Monogr. 11, 181-187 (1992).
16. Di Marco E, Pierce JH, Fleming TP et al. Autocrine interaction between TGF α and the EGF-receptor: quantitative requirements for induction of the malignant phenotype. Oncogene 4(7), 831-838 (1989).
17. Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, Kitchen P. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J. Clin. Oncol. 11(10), 1936-1942 (1993).
18. Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20(3), 719-726 (2002).
19. Cobleigh MA, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17(9), 2639-2648 (1999).
20. Esteva FJ, Valero V, Booser D et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20(7), 1800-1808 (2002).
21. Burstein HJ, Harris LN, Marcom PK et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter Phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J. Clin. Oncol. 21(15), 2889-2895 (2003).
22. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344(11), 783-792 (2001).
23. Wood ER, Truesdale AT, McDonald OB et al. A unique structure for epidermal growth factor receptor bound to GW572016 (lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 64(18), 6652-6659 (2004).
24. Burris HA III, Hurwitz HI, Dees EC et al. Phase I study, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J. Clin. Oncol. 23(23), 5305-5313 (2005).
25. Burris HA 3rd. Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist 9 (Suppl. 3), 10-15 (2004).
26. Baulida J, Kraus MH, Alimandi M, Di Fiore PP, Carpenter G. All erbB receptors other than the epidermal growth factor receptor are endocytosis impaired. J. Biol. Chem. 271(9), 5251-5257 (1996).
27. Lenferink AEG, Pinkas-Kramarski R, van de Poll MLM et al. Differential endocytic routing of homo- and hetero-dimeric erbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO J. 17(12), 3385-3397 (1998).
28. Bence AK, Anderson EB, Halepota MA et al. Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects. Invest. New Drugs 23(1), 39-49 (2005).
29. Geyer CE, Martin A, Newstat B et al. Lapatinib (L) plus capecitabine (C) in HER2+ advanced breast cancer (ABC): genomic and updated efficacy data. Proc. Am. Soc. Clin. Oncol. 25(Suppl. 18), 1035 (2007).
30. Sonpavde G. Lapatinib plus capecitabine in breast cancer. N. Engl. J. Med. 356(14), 1471-1472 (2007).
31. Geyer CE, Forster J, Cameron MD. Lapatinib plus capecitabine in breast cancer. N. Engl. J. Med. 356(14), 1471-1472 (2007).
32. Stein SH, Gomez HL, Chavez MA et al. Interim results of a Phase II randomized study of lapatinib (GW572016) as first-line treatment for patients with FISH-amplified advanced or metastatic breast cancer. Eur. J. Cancer 3(Suppl.), 78 (2005).
33. Perez EA, Byrne JA, Hammond IW et al. Cardiac safety experience in 3127 patients treated with lapatinib. Ann. Oncol. 17(Suppl. 9), 1420 (2006).
34. Kannel WB. Incidence and epidemiology of heart failure. Heart Fail. Rev. 5(2), 167-173 (2000).
35. Fujimoto-Ouchi K, Sekiguchi F, More I. Preclinical study of continuous administration trastuzumab as combination therapy after disease progresses with trastuzumab monotherapy. Proc. Am. Assoc. Cancer Res. 46, 5062 (2005).
36. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351(4), 337-345 (2004).
37. Marty M, Cognetti F, Maraninchi D et al. Randomized Phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J. Clin. Oncol. 23(19), 4265-4274 (2005).
38. Altaha R, Crowell E, Hobbs G, Higa G, Abraham J. Increased risk of brain metastasis in patients with HER-2/neu- positive breast carcinoma. Cancer 103(3), 442-443 (2005).
39. Stemmler J, Kahlert S. Siekiera W et al. Brain metastases (BM) in patients treated with trastuzumab for HER overexpressing metastatic breast cancer (MBC): incidence and survival. J. Clin. Oncol. 23(Suppl. 16), Abstract 1568 (2005).
40. Lin NU, Carey LA, Liu MC et al. Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer. J. Clin. Oncol. 24(Suppl. 18, Part I) (2006) (Abstract 503).
41. Lin NU, Dieras V, Paul D et al. EGF105084, a Phase II study of lapatinib for brain metastases in patients (pts) with HER2+ breast cancer following trastuzumab (H) based systemic therapy and cranial radiotherapy (RT). Proc. Am. Soc. Clin. Oncol. 25(Suppl. 18), 1012 (2007).
42. Campone M, Bourbouloux E, Fumoleau P. Cardiac dysfunction induced by trastuzumab. Bull. Cancer 91 (Suppl. 3), 166-173 (2004).
43. Grazette LP, Boecker W, Matsui T et al. Inhibition of erbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy. J. Am. Coll. Cardiol. 44(11), 2231-2238 (2004).
44. Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res. 61(24), 8887-8895 (2001).
45. ECOG E1100: a Phase II trial of trastuzumab and gefitinib in patients with metastatic breast cancer that overexpress HER2/neu (erbB-2). Clin. Adv. Hematol. Oncol. 1, 237 (2003).
46. Baselga J, Albanell J, Ruiz A et al. Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J. Clin. Oncol. 23(23), 5323-5233 (2005).
47. Rampaul RS, Pinder SE, Nicholson RI, Gullick WJ, Robertson JF, Ellis IO. Clinical value of epidermal growth factor receptor expression in primary breast cancer. Adv. Anat. Pathol. 12(5), 272-273 (2005).
48. Tsutsui S, Kataoka A, Ohno S, Murakami S, Kinoshita J, Hachitanda Y. Prognostic and predictive value of epidermal growth factor receptor in recurrent breast cancer. Clin. Cancer Res. 8(11), 3454-3460 (2002).
49. von Minckwitz G, Jonat W, Fasching P et al. A multicentre Phase II study on geftinib in taxane- and anthracycline-pretreated metastatic breast cancer. Breast Cancer Res. Treat. 89(2), 165-172 (2005).
50. Modi S, D'Andrea G, Norton L et al. A Phase I study of cetuximab/ paclitaxel in patients with advanced-stage breast cancer. Clin. Breast Cancer 7(3), 270-277 (2006).
51. Alimandi M, Romano A, Curia MC et al. Cooperative signaling of erbB3 and erbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 10(9), 1813-1821 (1995).
52. Kokai Y, Myers JN, Wada T et al. Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts. Cell 58(2), 287-292 (1989).
53. Xia W, Liu L-H, Ho P, Spector NL. Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual. EGFR/ErbB2 kinase inhibitor GW72016. Oncogene 23(3), 646-653 (2004).
54. Segatto O, King CR, Pierce JH, DiFiore PP, Aaronson SA. Different structural alterations upregulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene. Mol. Cell Biol. 8(12), 5570-5574 (1988).
55. Colomer R, Montero S, Lluch A et al. Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin. Cancer Res. 6(6), 2356-2362 (2000).
56. 2-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer. Clin. Cancer Res. 8(2), 347-353 (2002).
57. Hirata A, Hosoi F, Miyagawa M et al. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells. Cancer Res. 65(10), 4253-4260 (2005).
58. Anido J, Matar P, Albanell J et al. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER-overexpressing breast cancer cells. Clin. Cancer Res. 9(4), 1274-1283 (2003).
59. Gamett DC, Pearson G, Cerione RA, Friedberg I. Secondary dimerization between members of the epidermal growth factor receptor family. J. Biol. Chem. 272(18), 12052-12056 (1997).
60. Levitzki A, Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science 267(5205), 1782-1788 (1995).
61. Wang SC, Lien HC, Xia W et al. Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor erbB-2. Cancer Cell 6(3), 251-261 (2004).